Integrated BioPharma(OTC) INBP

Integrated BioPharma makes vitamins and supplements for health-focused consumers. Its products help people meet daily nutrition needs. The company also supplies raw materials to other supplement makers.

What’s on the Shelf? Products and Services

• Contract Manufacturing (94.8% of revenue in the nine months ended March 31, 2025): Produces vitamins and supplements for distributors, marketers, and healthcare providers.
• Other Nutraceutical Businesses (5.2% of revenue in the nine months ended March 31, 2025): Includes branded products such as Peaceful Sleep and Wheatgrass, private label sales, warehousing and fulfillment, and raw material distribution.
• Private Label Supplements: Offers custom-branded vitamins and supplements for online sale.
• Warehousing and Fulfillment: Provides storage and shipping services for supplement businesses.
• Raw Materials Distribution: Supplies botanicals and minerals to other manufacturers.

Growth and Expansion: The Company’s Greatest Hits

• Entered the Luxembourg market and expanded international sales since 2024.
• Added new major customer in 2025, now 38% of Other Nutraceutical Businesses segment sales.
• Increased sales to customers outside top two in Contract Manufacturing in 2025.
• Launched new branded products and expanded private label offerings in recent years.
• Secured new $4 million credit facility with PNC Bank in 2025 to support operations.

What Makes Integrated BioPharma Stand Out?

The company combines contract manufacturing with branded and private label products, serving both large clients and retailers. Its international reach, especially in Luxembourg, diversifies revenue streams. Warehousing and fulfillment services add operational flexibility for customers.

Five Things You Need to Know

• Net sales were $40.18 million for nine months ended March 2025, up 6.9% year-over-year.
• Contract Manufacturing segment contributed 94.8% of net sales in the same period.
• International sales reached $7.77 million, 19.3% of total net sales, for nine months ended March 2025.
• Gross profit margin improved to 10.2% for nine months ended March 2025, up from 6.9% prior year.
• Two customers accounted for 83% of total net sales for nine months ended March 2025.

Bottom Line

Integrated BioPharma has evolved by blending contract manufacturing with branded products and international sales. Its business model relies on a few large customers but shows adaptability in product and market expansion.